Cure8 research brief
VTE is a serious, potentially preventable complication in children with newly diagnosed IBD. Identifying risk factors could help clinicians consider which pediatric patients might need closer monitoring or future prophylaxis strategies.
Pediatric patients with new IBD diagnoses, parents and caregivers of children with IBD, pediatric gastroenterologists, thrombosis specialists, and clinical researchers studying IBD complications.
This multisite matched case-control study (2019–2024) analyzed pediatric patients newly diagnosed with IBD and identified factors associated with early venous thromboembolism (VTE) occurring ≤30 days before to ≤90 days after diagnosis.
Lower hemoglobin and lower albumin, corticosteroid use, presence of a central line, and any surgery within 90 days of diagnosis were associated with early VTE; platelets, CRP, fecal calprotectin, family history, and BMI were not associated. The article is an abstract-level source (summary/abstract provided by the journal).
This record is presented as an abstract/summary from Crohn's & Colitis 360 describing a matched case-control study; it does not present detailed predictive model validation or interventional data. The sample was small (15 cases, 52 controls), so findings may need confirmation in larger cohorts before changing practice.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This study looks at upadacitinib in people with Crohn’s disease who did not respond to anti-TNF drugs — a common and challenging clinical situation.
The study provides real-world effectiveness and safety data for risankizumab in a largely difficult-to-treat Crohn's population, showing about half achieved corticosteroid-free clinical remission at 24 weeks —...
Noninvasive blood biomarkers that track IBD activity could reduce reliance on repeat endoscopy. If validated, serum galectin‑3 might complement fecal calprotectin and CRP to help identify active disease.
